Brief: Inventiva Says Positive Recommendation Of The Fifth DMC Of The Nativ3 Phase 3 Clinical Trial With Lanifibranor In Patients With Mash
30/10/2024 20:01
Oct 30 (Reuters) - Inventiva SA IVAA.PA :
* REG-INVENTIVA ANNOUNCES THE POSITIVE RECOMMENDATION OF THE
FIFTH
DMC OF THE NATIV3 PHASE 3 CLINICAL TRIAL WITH LANIFIBRANOR IN
PATIENTS WITH MASH
Source text: ID:nGNE2csTGr
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030